Key result
Sympathetic nervous system activity is regionalized in obesity, with preferential activation of muscle vasoconstrictor and renal sympathetic outflows that is reduced with weight loss.
Why the study?
Sympathetic nervous system activity contributes to obesity-related disease development and progression, but regionalized activation makes clinical assessment difficult, and whether targeting it directly improves obesity-related illness remains unknown.
Obesity is associated with regionalized sympathetic nervous system activation that contributes to end-organ dysfunction and improves with weight loss, suggesting the sympathetic nervous system as a potential therapeutic target.
Supports SNS as contributor to obesity complications; leaves open whether targeted modulation improves outcomes.
The increase in the prevalence of obesity and the concomitant rise in obesity-related illness have led to substantial pressure on health care systems throughout the world. While the combination of reduced exercise, increased sedentary time, poor diet, and genetic predisposition is undoubtedly pivotal in generating obesity and increasing disease risk, a large body of work indicates that the sympathetic nervous system (SNS) contributes to obesity-related disease development and progression. In obesity, sympathetic nervous activity is regionalized, with activity in some outflows being particularly sensitive to the obese state, whereas other outflows, or responses to stimuli, may be blunted, thereby making the assessment of sympathetic nervous activation in the clinical setting difficult. Isotope dilution methods and direct nerve recording techniques have been developed and utilized in clinical research, demonstrating that in obesity there is preferential activation of the muscle vasoconstrictor and renal sympathetic outflows. With weight loss, sympathetic activity is reduced. Importantly, sympathetic nervous activity is associated with end-organ dysfunction and changes in sympathetic activation that accompany weight loss are often reflected in an improvement of end-organ function. Whether targeting the SNS directly improves obesity-related illness remains unknown, but merits further attention.
No takes yet. Share an insight, caveat, or question.
Lambert et al. (2019) conducted a review in Obesity. Sympathetic nervous system activity was evaluated. Sympathetic nervous system activity is regionalized in obesity, with preferential activation of muscle vasoconstrictor and renal sympathetic outflows that is reduced with weight loss.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: